-
Je něco špatně v tomto záznamu ?
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
F. Efficace, FX. Mahon, J. Richter, A. Piciocchi, M. Cipriani, FE. Nicolini, J. Mayer, D. Zackova, JJWM. Janssen, P. Panayiotidis, H. Vestergaard, P. Koskenvesa, A. Almeida, H. Hjorth-Hansen, J. Martinez-Lopez, U. Olsson-Strömberg, A. Hochhaus,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2024-01-01 do Před 1 rokem
- MeSH
- chronická myeloidní leukemie * farmakoterapie MeSH
- dospělí MeSH
- inhibitory tyrosinkinasy * terapeutické užití MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- přerušení léčby MeSH
- průzkumy a dotazníky MeSH
- senioři MeSH
- únava chemicky indukované MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.
Bergonié Cancer Institute INSERM UMR1312 Inserm University of Bordeaux Bordeaux France
Centre Léon Bérard Service d'Hématologie Clinique and INSERM U1052 CRCL Lyon France
Department of Haematology Odense University Hospital Odense Denmark
Department of Haematology Oncology and Radiation Physics Skåne University Hospital Lund Sweden
Department of Hematology Radboud UMC Nijmegen The Netherlands
Department of Statistical Sciences Sapienza University of Rome Rome Italy
Faculdade de Medicina Universidade Católica Portuguesa Lisbon Portugal
France Intergroupe de la leucémie myéloïde chronique Fi LMC Lyon France
Hematology Research Unit Helsinki and HUS Cancer Center Hematology Line Helsinki Finland
Hospital 12 de Octubre CNIO i 12 Department of Medicine Univ Complutense Madrid Spain
Hospital da Luz Lisbon Portugal
Institut Bergonié département d'hématologie Bordeaux France
Institute of Hematology and Blood Transfusion Prague Czech Republic
Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany
Laikon General Hospital National and Kapodistrian University of Athens Athens Greece
Medical Clinic Medical Faculty Mannheim Heidelberg University Mannheim Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019476
- 003
- CZ-PrNML
- 005
- 20241024110812.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02341-4 $2 doi
- 035 __
- $a (PubMed)38987274
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Efficace, Fabio $u Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy. f.efficace@gimema.it $1 https://orcid.org/0000000250655166
- 245 10
- $a Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial / $c F. Efficace, FX. Mahon, J. Richter, A. Piciocchi, M. Cipriani, FE. Nicolini, J. Mayer, D. Zackova, JJWM. Janssen, P. Panayiotidis, H. Vestergaard, P. Koskenvesa, A. Almeida, H. Hjorth-Hansen, J. Martinez-Lopez, U. Olsson-Strömberg, A. Hochhaus, MG. Berger, G. Etienne, H. Klamova, E. Faber, P. Rousselot, M. Pfirrmann, S. Saussele
- 520 9_
- $a Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a únava $x chemicky indukované $7 D005221
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $7 D015464
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 12
- $a inhibitory tyrosinkinasy $x terapeutické užití $7 D000092004
- 650 _2
- $a přerušení léčby $7 D000097042
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Mahon, Francois-Xavier $u Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France
- 700 1_
- $a Richter, Johan $u Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden $1 https://orcid.org/0000000203746823
- 700 1_
- $a Piciocchi, Alfonso $u Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy $1 https://orcid.org/000000018648885X
- 700 1_
- $a Cipriani, Marta $u Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy $u Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy $1 https://orcid.org/0000000161598059
- 700 1_
- $a Nicolini, Franck E $u Centre Léon Bérard, Service d'Hématologie Clinique & INSERM U1052 CRCL, Lyon, France
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000198028148 $7 xx0074334
- 700 1_
- $a Janssen, Jeroen J W M $u Department of Hematology, Radboud UMC, Nijmegen, The Netherlands $1 https://orcid.org/0000000195671955
- 700 1_
- $a Panayiotidis, Panayiotis $u Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Vestergaard, Hanne $u Department of Haematology, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Koskenvesa, Perttu $u Hematology Research Unit Helsinki and HUS Cancer Center, Hematology Line, Helsinki, Finland
- 700 1_
- $a Almeida, Antonio $u Faculdade de Medicina, Universidade Católica Portuguesa, Lisbon, Portugal $u Hospital da Luz, Lisbon, Portugal $1 https://orcid.org/0000000343610928
- 700 1_
- $a Hjorth-Hansen, Henrik $u St Olavs Hospital HF, Trondheim, Norway $1 https://orcid.org/0000000226705696
- 700 1_
- $a Martinez-Lopez, Joaquin $u Hospital 12 de Octubre, CNIO, i+12, Department of Medicine Univ. Complutense, Madrid, Spain
- 700 1_
- $a Olsson-Strömberg, Ulla $u Department of Medical Sciences, Uppsala University and Hematology Section, Uppsala University Hospital, Uppsala, Sweden
- 700 1_
- $a Hochhaus, Andreas $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany $1 https://orcid.org/0000000306260834
- 700 1_
- $a Berger, Marc G $u CHU Clermont-Ferrand, Hematology department, and EA 7453 CHELTER, University Clermont Auvergne, Clermont-Ferrand, France
- 700 1_
- $a Etienne, Gabriel $u Institut Bergonié, département d'hématologie, Bordeaux, France $u France Intergroupe de la leucémie myéloïde chronique Fi-LMC, Lyon, France
- 700 1_
- $a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0009000050207040 $7 xx0081721
- 700 1_
- $a Faber, Edgar $u Department of Hemato-oncology, Faculty Hospital and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Rousselot, Philippe $u Centre Hospitalier de Versailles, Department of Haematology, University Versailles Paris-Saclay, Le Chesnay, France
- 700 1_
- $a Pfirrmann, Markus $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, LMU München, München, Germany $1 https://orcid.org/0000000289480690
- 700 1_
- $a Saussele, Susanne $u Medical Clinic, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany $1 https://orcid.org/0000000303575785
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 8 (2024), s. 1722-1730
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38987274 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110806 $b ABA008
- 999 __
- $a ok $b bmc $g 2201985 $s 1231449
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 8 $d 1722-1730 $e 20240710 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20241015
